-
公开(公告)号：US20240425617A1
公开(公告)日：2024-12-26
申请号：US18638545
申请日：2024-04-17
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Tina BUCH , Christian GRAF , Daniel HEITMANN , Thomas JOSTOCK , Hans-Peter KNOPF , Rolf KOEHLER , Jiri KOVARIK , Stephen John OLIVER , Dhavalkumar PATEL , Maximilian WOISETSCHLAEGER
Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.
-
公开(公告)号：US20220098296A1
公开(公告)日：2022-03-31
申请号：US17386429
申请日：2021-07-27
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Barbara BRANNETTI , Emma Michelle CAMPBELL , Beate DIEFENBACH-STREIBER , Adina EBERTH , Christian Carsten Silverster KUNZ , Sylwia MARSHALL , Jean-Michel Rene RONDEAU , Jean-Marc Alfred SCHLAEPPI , Gino Anselmus VAN HEEKE
Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
-
Patent Agency Ranking
公开(公告)号：US20250034240A1
公开(公告)日：2025-01-30
申请号：US18634286
申请日：2024-04-12
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Barbara BRANNETTI , Emma Michelle CAMPBELL , Beate DIEFENBACH-STREIBER , Adina EBERTH , Christian Carsten Silvester KUNZ , Sylwia MARSHALL , Jean-Michel RONDEAU , Jean-Marc Alfred SCHLAEPPI , Gino Anselmus VAN HEEKE
Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
-
公开(公告)号：US20230357381A1
公开(公告)日：2023-11-09
申请号：US18306958
申请日：2023-04-25
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Regis CEBE , Jiri KOVARIK , Frank KOLBINGER , Michael KIFFE , Anett RITTER , Lukas ROTH
IPC: C07K16/24 , A61K39/395 , A61P17/00
CPC classification number: C07K16/244 , A61K39/3955 , A61P17/00 , A61K2039/505
Abstract: Described herein are multispecific antibodies targeting IL-13 and IL-18. The multispecific antibodies can be antagonistic and/or therapeutic antibodies targeting IL-13 and IL-18. Also described herein are methods of making said multispecific antibodies, methods of inhibiting IL-13 and IL-18 simultaneously with said multispecific antibodies, and methods of treating an IL-13/IL-18 mediated disorder, such as atopic dermatitis, by administering a multispecific antibody described herein.
-
5.发明申请公开(公告)号：US20200308309A1
公开(公告)日：2020-10-01
申请号：US16844999
申请日：2020-04-09
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Tina BUCH , Christian GRAF , Daniel HEITMANN , Thomas JOSTOCK , Hans-Peter KNOPF , Rolf KOEHLER , Jiri KOVARIK , Stephen John OLIVER , Dhavalkumar PATEL , Maximilian WOISETSCHLAEGER
Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.
-
公开(公告)号：US20190085068A1
公开(公告)日：2019-03-21
申请号：US16111659
申请日：2018-08-24
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Barbara BRANNETTI , Emma Michelle CAMPBELL , Beate DIEFENBACH-STREIBER , Adina EBERTH , Christian Carsten Silverster KUNZ , Sylwia MARSHALL , Jean-Michel Rene RONDEAU , Jean-Marc Alfred SCHLAEPPI , Gino Anselmus VAN HEEKE
Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
-
7.发明申请公开(公告)号：US20190002589A1
公开(公告)日：2019-01-03
申请号：US16005088
申请日：2018-06-11
Applicant: NOVARTIS AG
Inventor： Michael Otto BARDROFF , Tina BUCH , Christian GRAF , Daniel HEITMANN , Thomas JOSTOCK , Hans-Peter KNOPF , Rolf KOEHLER , Jiri KOVARIK , Stephen John OLIVER , Dhavalkumar PATEL , Maximilian WOISETSCHLAEGER
Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.
-
-
-
-
-
-
Search Results
7
records
(took 0.023 seconds)
